Comparative efficacy of spironolactone, eplerenone, nebivolol and moxonidine in patients with resistant arterial hypertension
Article Sidebar
Main Article Content
Abstract
The aim – to study the effectiveness of spironolactone, eplerenone, nebivolol, moxonidine as the 4th component of therapy in patients with resistant arterial hypertension.
Material and methods. The study involved 66 patients with true resistant arterial hypertension (RAH). The average age of patients was 51.9±1.2 years, mostly men (59.1 %). In addition to standard triple-dose fixed combination antihypertensive tharepy, all patients received in turn spironolactone (45.0±3.6 mg/day), eplerenone (47.9±2.1
mg/day), nebivolol (8.9±0.6 mg/day) and moxonidine (0.5±0.1 mg/day). After completion of each stage, after
3 months of therapy, all patients have been assessed an office blood pressure measurements and ABPM.
Results. In patients with RAH, the addition standardized therapy with a triple fixed-dose combination of antihypertensive drugs, antagonists of mineralocorticoid showed better effectiveness than nebivolol and moxonidine: the target level of BP with treatment of spironolactone was achieved in 68.2 % patients, eplerenone – 65.2 %, whereas in the groups of nebivolol and moxonidine – in 53.9 % and 56.2 %, respectively. The predictors of the effectiveness of the antagonists of the mineralocorticoid receptors are increasing plasma aldosterone concentrations (β=0.653; Р=0.002) and ARR values (β=0.542; Р=0.003), while the β-blocker and imidazolin receptor agonist were more effective in older patients (β=0.425; Р=0.02) along with increase of average daily pulse (β=0.315; P=0.04) and excretion of urine metanephrines (β=0.382; Р=0.01).
Conclusoins. Spironolactone and eplerenone are drugs of choice for adding to triple fixed-dose combination in patients with RAH. They were significantly more effective than beta-blocker (nebivolol) and an imidazolin receptor agonist (moxonidine).
Article Details
Keywords:
References
Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370(15):1393-1401. doi: 10.1056/NEJMoa1402670.
Bramlage P, Turgonyi E, Montalescot G. Aldosterone blockade: current research and future trends. European Heart Journal Supplements 2011;13(suppl B):B46–B50. doi.org/10.1093/eurheartj/sur005.
Calhoun D, White W. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008;2(6):462–468.
Carey R, Whelton P; 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med 2018;168(5):351-358. doi: 10.7326/M17-3203. Epub 2018 Jan 23.
Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, Russell RP. The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies. Am J Hypertens 2015;28(11):1376-1385. doi: 10.1093/ajh/hpv031.
Doumas M, Tsioufis C, Faselis C, Lazaridis A, Grassos H, Papademetriou V. Non-interventional management of resistant hypertension. World J Cardiol 2014;6(10):1080-1090. doi: 10.4330/wjc.v6.i10.1080
Kasiakogias A, Tsioufis C, Dimitriadis K, Konstantinidis D, Koumelli A. Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives: a 4-year follow-up study. J Hum Hypertens 2018; 32(7):487-493. doi: 10.1038/s41371-018-0065-y.
Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007;25(4):891–894. https://www.ncbi.nlm.nih.gov/pubmed/17351384
Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials. Clin Exp Hypertens A 2017;39(3):257–263.
Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. Task Force Members 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31(7):1281–1357. doi: 10.1097/01.hjh.0000431740.32696.cc.
Pioli M, Ritter A, Modolo R. Un-sweetening the Heart: Possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects. Am J Hypertens 2018;31(3):274-280. doi: 10.1093/ajh/hpx204.
Rosa J, Widimský P, Waldauf P, Lambert L, Zelinka T, Táborský M, Branny M, Toušek P, Petrák O, Čurila K, Bednář F, Holaj R, Štrauch B, Václavík J, Nykl I, Krátká Z, Kociánová E, Jiravský O, Rappová G, Indra T, Widimský J Jr. Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study. Hypertension 2016;67(2):397–403. doi: 10.1161/HYPERTENSIONAHA.115.06526.
Savoia C, Schiffrin E. Reduction of C-reactive protein and the use of anti-hypertensives. Vasc Health Risk Manag 2007;3(6):975–983.
Sinnott SJ, Tomlinson LA, Root AA, Mathur R, Mansfield KE, Smeeth L, Douglas IJ. Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis. Eur J Prev Cardiol 2017;24(3);228–238. doi: 10.1177/2047487316675194.
Vaclavik J, Sedlak R, Jarkovsky J, Kocianova E, Taborsky M. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). Medicine (Baltimore) 2014;93(27):e162.
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386(10008):2059–2068. doi: 10.1016/S0140-6736(15)00257-3.
Yugar-Toledo J, Modolo R, de Faria A, Moreno H. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists. Vasc Health Risk Manag 2017;13:403–411.